Shots :
- The P-III (HYPERION) study evaluating Winrevair vs PBO (both in combination with background therapy) in recently diagnosed adults (N=320, >18) with PAH (WHO Group 1) functional class (FC) II or III at intermediate or high risk of disease progression
- The study met its 1EP of TTCW measured by the first confirmed morbidity or mortality event. At 24wks., 2EP were assessed relative to baseline, incl. the proportion of pts with multicomponent improvement and additional measures
- P-III study stopped early and moved to final analysis due to positive interim results, following the STELLAR & ZENITH studies, and the company is expecting to present the data at an upcoming medical meeting & will be submitted to regulatory authorities later this year
Ref: Merck| Image: Merck| Press Release
Related News:- Madrigal Pharmaceuticals’ Rezdiffra Receives the CHMP’s Positive Opinion for MASH with Liver Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
